NASDAQ:ECYT - Endocyte Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$23.99
+0.30 (1.20%)
Get New Endocyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ECYT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ECYT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Endocyte in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $23.99.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Endocyte. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/2/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/19/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformLow
i
10/18/2018WedbushDowngradeOutperform ➝ NeutralLow
i
Rating by D. Nierengarten at Wedbush
9/10/2018CowenReiterated RatingBuyHigh
i
8/2/2018Jefferies Financial GroupReiterated RatingBuy$21.00Low
i
7/16/2018WedbushBoost Price TargetOutperform ➝ Outperform$15.00 ➝ $21.00High
i
4/13/2018Jefferies Financial GroupInitiated CoverageBuy ➝ BuyHigh
i
3/9/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformHigh
i
2/27/2018CowenUpgradeMarket Perform ➝ OutperformHigh
i
10/3/2017WedbushUpgradeNeutral ➝ Outperform$2.00 ➝ $7.00High
i
Rating by D. Nierengarten at Wedbush
10/2/2017CowenReiterated RatingHoldHigh
i
Rating by Boris Peaker at Cowen Inc
6/5/2017WedbushDowngradeOutperform ➝ Neutral$8.00 ➝ $2.00High
i
Rating by D. Nierengarten at Wedbush
6/2/2017CowenDowngradeOutperform ➝ Market PerformLow
i
Rating by Boris Peaker at Cowen Inc
5/11/2017WedbushReiterated RatingOutperformHigh
i
4/5/2017CowenReiterated RatingBuyLow
i
11/11/2016Credit Suisse GroupReiterated RatingBuy$7.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/4/2016CowenReiterated RatingBuyN/A
i
Rating by Boris Peaker at Cowen Inc
5/4/2016WedbushReiterated RatingOutperform$8.00N/A
i
Rating by David Nierengarten at Wedbush
3/7/2016CowenReiterated RatingOutperformN/A
i
3/2/2016WedbushReiterated RatingOutperform$12.00 ➝ $8.00N/A
i
(Data available from 1/25/2016 forward)
Endocyte logo
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.
Read More

Today's Range

Now: $23.99
$23.99
$23.99

50 Day Range

MA: N/A

52 Week Range

Now: $23.99
$2.81
$24.00

Volume

N/A

Average Volume

2,117,754 shs

Market Capitalization

$1.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Endocyte?

The following Wall Street sell-side analysts have issued stock ratings on Endocyte in the last twelve months:

What is the current price target for Endocyte?

0 Wall Street analysts have set twelve-month price targets for Endocyte in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Endocyte in the next year.

What is the current consensus analyst rating for Endocyte?

Endocyte currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."

What other companies compete with Endocyte?

How do I contact Endocyte's investor relations team?

Endocyte's physical mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company's listed phone number is 765-463-7175. The official website for Endocyte is www.endocyte.com.